Abstract
Due to variations in the regulatory norms of registration dossier in different countries, there is a strong need for harmonization by ICH for approval of drugs. Generic drugs in EU are approved under the Marketing Authorization Application. Bioavailability and Bioequivalence study data is critical in the generic drug approval process. Moreover, there are several approaches to assess BA/BE, each regulatory authority has put forth its own regulations/guidances for conducting BA/BE studies. Medicinal products are highly regulated in the European Union (EU) and are subject to a separate, complicated system of approvals that governs how, when, where, and in what form such products will be allowed to be sold within the borders of EU. The present marketing authorization procedures applicable to European Economic Area included 27 EU member states and the three EEA European Free Trade Association states (Iceland, Liechtenstein and Norway). Marketing Authorization Application is applied based on National procedure, mutual recognition procedure, centralized and decentralized procedure. Hence procedure for Registration of Drug Products was discussed in detail in this current review.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
